![Merus N.V. logo](/logos/MRUS.webp)
Merus N.V.
NASDAQ:MRUS
Overview | Financials
Company Name | Merus N.V. |
Symbol | MRUS |
Currency | USD |
Price | 50 |
Market Cap | 3,410,525,000 |
Dividend Yield | 0% |
52-week-range | 19.805 - 61.61 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sven Ante Lundberg M.D. |
Website | https://www.merus.nl |
An error occurred while fetching data.
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD